Hepatitis C virus immunogenic compositions and methods of use thereof

US11576967B2 · kind B2 · utility

Assignee

• The Governors of the University of Alberta · CA

Inventors

• Michael Houghton · Berkeley, US
• John L. Law · Edmonton, CA
• Michael Logan · Edmonton, CA
• Darren Hockman · Edmonton, CA
• Abdolamir Landi · Edmonton, CA

Key dates

• Filing date: Dec 15, 2020
• Grant date: Feb 14, 2023
• Expiry date: Aug 17, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2770/24234
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides heterodimeric polypeptides comprising: 1) a variant hepatitis C virus (HCV) E2 polypeptide and an HCV E1 polypeptide; 2) a variant HCV E1 polypeptide and an HCV E2 polypeptide; or 3) a variant HCV E1 polypeptide and a variant HCV E2 polypeptide, where the variant HCV E2 polypeptide and/or the HCV E1 polypeptide comprises one or more T cell epitopes, present in an HCV polypeptide other than an HCV E1 polypeptide or an HCV E2 polypeptide. The present disclosure provides nucleic acids encoding a polyprotein that includes E1 and variant E2, E2 and variant E1, or variant E2 and variant E1. The present disclosure provides a method of producing an E1/E2 heterodimer of the present disclosure. The present disclosure provides a method of inducing an immune response in an individual. The present disclosure provides variant E2 polypeptides and variant E1 polypeptides; and nucleic acids encoding same.